Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Alexander Fanaroff Added: 1 year ago
AHA 2023 — We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease… View more
Author(s): Marielle Scherrer-Crosbie Added: 1 year ago
ACC.23/WCC — In this succinct late-breaking science interview, Investigator, Dr Marielle Scherrer-Crosbie (Hospital of the University of Pennsylvania, US) discusses the results from the STOP-CA trial (Massachusetts General Hospital). This randomized phase II trial aims to investigate whether atorvastatin, a commonly prescribed statin drug for reducing cholesterol levels, can protect the heart… View more
Author(s): Marc P Bonaca Added: 2 months ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more
Author(s): Paul M Ridker Added: 1 year ago
ACC.23/WCC - We are joined by Dr Paul Ridker (Brigham and Women’s Hospital, US) to discuss the findings from a collaborative analysis of 31,197 patients to assess inflammatory risk in statin-treated patients. The PROMINENT, REDUCE-IT and STRENGTH trials were each large contemporary trials which implemented guideline-directed medical therapy, the findings of which were pooled in this study. The… View more
Author(s): Harriette Van Spall , Steven E Nissen Added: 1 year ago
ACC.23/WCC — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) to have a deep dive into the practice-changing CLEAR-Outcomes trial (NCT02993406).The Phase 3 CLEAR-Outcomes trial was conducted to evaluate the impact of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular… View more
Author(s): Enoch Akowuah , Annapoorna Kini , Atul Verma , et al Added: 1 year ago
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen(Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data. For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall(McMaster University, Hamilton, CA)… View more
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
Prof Nicolas Van Mieghem and Dr Joost Daemen return with their critical review series, View from the Thoraxcenter, to preview the most anticipated late-breaking and featured science trials of ACC.23. Which trials have the potential to change practice? What are the key considerations for patient care and research? What is the context of the top trials of ACC? Trials covered in detail include: … View more